治疗前CT上的强化或灌注能否预测肝细胞癌栓塞术后的结局
回顾性分析63例肝细胞癌患者,于2009年3月至2014年12月接受颗粒栓塞治疗,在治疗前三相CT上对靶肿瘤及背景肝进行定量强化与灌注测量,并与病理、改良RECIST疗效及总生存做相关分析;结果显示动脉期强化、分化程度及微血管侵犯均不能预测即刻疗效或总生存,而肿瘤及背景肝的高肝动脉系数或低门静脉系数与更差生存相关。
要点
- 治疗前三相CT测量的肿瘤及背景肝灌注参数(肝动脉系数、门静脉系数)可预测颗粒栓塞术后生存。
- 动脉期强化、肿瘤分化程度及微血管侵犯均不能预测栓塞术后即刻疗效或总生存。
- 肿瘤及背景肝的高肝动脉系数或低门静脉系数与更差生存相关。
核心结论
- 治疗前三相CT估算的肿瘤及肝灌注参数可预测颗粒栓塞术后生存;动脉期强化与组织学(分化程度或微血管侵犯)不能预测即刻疗效或总生存。
研究设计与样本
- 回顾性研究,经机构审查委员会批准,纳入2009年3月至2014年12月间接受颗粒栓塞治疗的63例肝细胞癌患者,于治疗前三相CT上对靶肿瘤及背景肝行定量强化与灌注测量,微血管侵犯及分化程度由粗针活检标本确定。
诊断标准与关键数值
- 动脉期强化不能预测栓塞术后即刻疗效或总生存;分化程度或微血管侵犯的存在也不能预测即刻疗效或总生存;肿瘤内高肝动脉系数(P = .011)或低门静脉系数(P = .004)以及背景肝内高肝动脉系数(P = .015)或低门静脉系数(P = .009)与更差生存相关;在纳入Child-Pugh评分及BCLC分期的多变量模型中,肿瘤内肝动脉系数(P = .025)及背景肝内肝动脉系数(P = .013)为生存的独立预测因子。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVE: The objective of this study was to evaluate whether quantitative enhancement or perfusion measurements on preprocedure triphasic computed tomography (CT) can be used to predict response or overall survival after embolization of hepatocellular carcinoma.
MATERIALS AND METHODS: The institutional review board approved this retrospective review of 63 patients with hepatocellular carcinoma treated with particle embolization between March 2009 and December 2014. Quantitative enhancement and perfusion measurements were performed on the target tumor and the background liver on the triphasic CT performed before treatment. Microvascular invasion (MVI) and degree of differentiation were determined from a core biopsy specimen. Quantitative enhancement and perfusion values were then correlated with pathology (two-tailed t test), response to embolization on modified Response Evaluation Criteria In Solid Tumors (two-tailed t test), and overall survival after embolization (Cox proportional hazards model).
RESULTS: Arterial enhancement did not predict immediate response or overall survival after embolization. The degree of differentiation or presence of MVI also did not predict immediate response or overall survival after embolization. However, high hepatic artery coefficient or low portal vein coefficient, both in the tumor (P = .011 and P = .004) and in the background liver (P = .015 and P = .009), were associated with worse survival. Hepatic artery coefficient, both in the tumor (P = .025) and in the background liver (P = .013), were independent predictors of survival in a multivariate model including the Child-Pugh score and the BCLC stage.
CONCLUSIONS: Tumor and liver perfusion parameters estimated from preprocedure triphasic CT were predictive of survival after embolization. Arterial-phase enhancement and histology (degree of differentiation or MVI) did not predict immediate response or overall survival after particle embolization.
引用
- Borgheresi A, Gonzalez-Aguirre A, Brown KT, et al. Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma? Acad Radiol. 2018. PMID: 29602726. doi:10.1016/j.acra.2018.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。